Login    Join free Add to favorites    中文
Home >Products> Reagents >Antibody> Tau (phospho T181) Mouse mAb (SDT-200-9)
Tau (phospho T181) Mouse mAb (SDT-200-9)
Tau (phospho T181) Mouse mAb (SDT-200-9)
Origin of place Singapore
Model S0B3157-1mg
Supplier ANT BIO PTE.LTD.
Price 835
Hits 0
Updated 8/27/2025
  • Product Detail
  • Company Profile

Product Specification


HostMouse
AntigenTau (phospho T181)
Synonymsp-Tau181, phospho T181
ImmunogenSynthetic Peptide
AccessionP10636
Clone NumberSDT-200-9
Antibody TypeMouse mAb
IsotypeIgG1,k
ApplicationSandwich ELISA
ReactivityHu, Ms
Predicted ReactivityHu, Ms
Cross ReactivityDoes not recognize total Tau
PurificationProtein G
Concentration5 mg/ml
Purity>95% by HPLC
ConjugationUnconjugated
Physical AppearanceLiquid
Storage Buffer

PBS pH7.4, 0.03% Proclin 300

Stability & Storage

12 months from date of receipt, 2 to 8 °C as supplied

Dilution


applicationdilutionspecies
Sandwich ELISAN/A

Background

Accumulation of intraneuronal neurofibrillary tangles (NFTs) containing paired helical filaments (PHFs) of the microtubule-associated protein tau is one of the defining neuropathological hallmarks of Alzheimer’s disease (AD). The tau protein has an N-terminal projection domain, a proline-rich region, a repeat region, and a C-terminal domain, with multiple potential phosphorylation sites along all regions. Studies using preparations of PHFs and immunohistochemical staining of postmortem brain tissue with specific tau antibodies established that PHF tau is hyperphosphorylated. High levels of p-tau and total tau (t-tau) have consistently been found in cerebrospinal fluid (CSF) of AD patients. However, while CSF t-tau is considered a non-specific biomarker of neuronal injury, p-tau may reflect AD-related tau pathology in the brain. The vast majority of CSF studies have used immunoassays detecting tau phosphorylated at threonine (Thr) 181 (p-tau181). During the last 2 decades, CSF p-tau181 together with total tau (t-tau) and amyloid-β 42 (Aβ42) have been extensively validated as biomarkers of AD and are currently widely used as diagnostic criteria in research studies, in clinical practice in some countries, and for patient selection in clinical trials. CSF p-tau181 (alone or in combination with Aβ42) accurately differentiates AD from controls and predicts cognitive decline in preclinical and prodromal disease stages. CSF p-tau181 levels are higher in AD compared with other tauopathies including frontotemporal dementia (FTD), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) and, hence, CSF p-tau181 has also been proven useful in differential diagnosis of dementia.

bio-equip.cn
Request Infomation

* Name:
Title:
* Tel:
Fax:
* E-mail:
Postcode:
Institution/Company:
Address:
* Country:
Request infomation:
yes no
Request Quotation:
yes no
* Message:
Validated Code:
refresh
I agree to share my inquiry to the other matching suppliers.



Copyright(C) 2006-2025 Bio-Equip    E-mail:web@bio-equip.cn   沪ICP备06040519号